Marrow Therapeutics launched with $173 million in Series A and B funding to pursue a gene-therapy-competitive approach for sickle cell and beta thalassemia without relying on gene transfer or editing, according to STAT+. The startup—founded by biotech entrepreneur Romesh Subramanian—frames its strategy as a more accessible alternative for severe blood diseases. The company is positioning the program as targeting outcomes comparable to gene therapy “in patients” while navigating the key drawbacks that have limited adoption, including logistics, manufacturing complexity, and long-term durability questions. For investors and biotech operators, the funding underscores continued appetite for next-generation curative modalities that address the access and scaling limitations of approved gene therapies.
Get the Daily Brief